Navigation Links
Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence
Date:11/30/2009

BOSTON and COPENHAGEN, Nov. 30 /PRNewswire/ -- Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") announced today that the Harvard Medical School ICCB-Longwood Screening Facility (ICCB-L) has been recognized as a MicroRNA Screening Center of Excellence. ICCB-L supports investigators at Harvard Medical School, and associated hospitals and institutions, for high-throughput screening of small molecule and RNAi libraries.

MicroRNAs are a novel class of small, non-coding RNA species, which have been shown to play a major role in post-transcriptional processing of messenger RNA, including the regulation of many physiological and pathological processes, such as cellular development, cancer, apoptosis, aging, metabolic diseases, and immune responses. The external modulation of microRNA expression levels has been shown to have dramatic impact on cellular phenotype, a result which has promoted the functional analysis of microRNA to the forefront of translational medicine.

ICCB-L will provide the Exiqon LNA(TM) microRNA Knockdown Library as a screening tool for a new consortium of Harvard-affiliated investigators, coordinated by Dr. Neil Kubica of the Blenis Laboratory at Harvard Medical School. The consortium has developed multiple biological models that will be interrogated with the Knockdown Library. The Library contains over 900 specific inhibitors designed for uniform potency, made possible through the incorporation of Exiqon's proprietary LNA(TM) technology.

"My colleagues and I look forward to screening the Knockdown Library. There is a great deal of interest in our community in using miRNA knockdown reagents to study disease-related biology," says Dr. Kubica.

Exiqon recently unveiled its microRNA Centers of Excellence Program -- which has categories for microRNA Profiling (Expression), microRNA detection and imaging (Localization), and microRNA functional studies (Screening) -- to help provide a set of reference laboratories and institutions for researchers new to the field of microRNA study. "More and more researchers are recognizing the importance and relevance of microRNA in their own biological systems under study. But with a variety of methods and solutions from different providers, sometimes researchers aren't sure where to start. It can be overwhelming," says Tom Bishop, Site Director for Exiqon North America. "The microRNA Centers of Excellence are meant to be a roadmap of sorts for researchers new to microRNA -- a panel of experts who demonstrate best-in-class tactics and approaches to microRNA studies."

The microRNA Centers of Excellence Program serves as an example of the collaborative spirit in which microRNA research has blossomed over recent years, according to Exiqon officials. "Exiqon has always been committed to bringing exceptional value in the tools and solutions we provide microRNA researchers, but this is only one piece of the puzzle," says Chris Harbert, Director of Marketing for Exiqon North American Life Sciences. "The real magic occurs when excellence in research tools is combined with excellence in experimental design and implementation. That's what these microRNA Centers of Excellence will bring to the table."

ICCB-L represents the first institution to be inducted as an Exiqon microRNA Center of Excellence, in the area of functional studies. Exiqon is currently accepting other Center of Excellence applications in all categories. Interested parties are invited to contact their local representative, or to contact Chris Harbert, Director of Marketing, at (888) 647-2879.

About Exiqon

Exiqon operates in two business segments sharing one vision: the idea of taking science to patients through personalized medicine; one focus: the promise of miRNA as biological markers; and one technology platform: our proprietary LNA(TM) (Locked Nucleic Acid) detection technology with its unique competitive advantages in the markets we address. Exiqon Life Sciences has established a position for itself as one of the market's leading providers of research products for gene expression analysis. Our products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries in the field of gene expression analysis. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biological markers (Pharma Services). Exiqon Diagnostics is a leading provider of cellular based diagnostics for cancer treatment selection. We are developing a series of new molecular diagnostic tests for high incidence cancers based on miRNA biomarkers. The first test has been developed, and additional tests are in the pipeline for each coming year. Exiqon has approximately 170 employees and is listed on the NASDAQ OMX in Copenhagen. For more information about Exiqon, visit www.exiqon.com.

Disclaimer

Forward-looking statements:

This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.


Contact:
Chris Harbert
Exiqon Director of Marketing
888-647-2879
cha@exiqon.com

SOURCE Exiqon


'/>"/>
SOURCE Exiqon
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists
2. Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S
3. Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer
4. Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc.
5. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
6. Report Regarding the Managements and Closely Related Parties Transactions With Securities in Exiqon A/S
7. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
8. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
9. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
10. Exiqon: Major Shareholder Announcement
11. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... San Diego, CA (PRWEB) , ... May 26, ... ... assay development and manufacturing company, today announced several positive developments that position the ... As a result of the transaction, Craig F. Kinghorn has been appointed ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice Hand ... and surgery of the hand by the National Board of Physicians and Surgeons, ... and beyond in his pursuit of providing the most comprehensive, effective treatment for ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company ... granted the company’s orphan drug designation request covering BHV-4157 for the treatment of ... the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and across ... South Texas Blood & Tissue Center, blood donations are on the decline. In fact, donations ... are down 21 percent in South Texas in the last four years alone. , There ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):